Format

Send to

Choose Destination
Brain Pathol. 2016 Jul;26(4):452-64. doi: 10.1111/bpa.12292. Epub 2015 Sep 22.

A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset.

Author information

1
Institute of Neuropathology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
2
Department of Cognitive Neurology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
3
Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
4
Clinical Neurobiology Laboratory, German Primate Center, Göttingen, Germany.
5
Teva Pharmaceutical Industries, Netanya, Israel.
6
Encepharm GmbH, Göttingen, Germany.
7
Department of Neurology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.

Abstract

Multiple sclerosis (MS) is the most common cause for sustained disability in young adults, yet treatment options remain very limited. Although numerous therapeutic approaches have been effective in rodent models of experimental autoimmune encephalomyelitis (EAE), only few proved to be beneficial in patients with MS. Hence, there is a strong need for more predictive animal models. Within the past decade, EAE in the common marmoset evolved as a potent, alternative model for MS, with immunological and pathological features resembling more closely the human disease. However, an often very rapid and severe disease course hampers its implementation for systematic testing of new treatment strategies. We here developed a new focal model of EAE in the common marmoset, induced by myelin oligodendrocyte glycoprotein (MOG) immunization and stereotactic injections of proinflammatory cytokines. At the injection site of cytokines, confluent inflammatory demyelinating lesions developed that strongly resembled human MS lesions. In a proof-of-principle treatment study with the immunomodulatory compound laquinimod, we demonstrate that targeted EAE in marmosets provides a promising and valid tool for preclinical experimental treatment trials in MS research.

KEYWORDS:

common marmoset; demyelination; experimental autoimmune encephalomyelitis; immunomodulation; laquinimod; multiple sclerosis

PMID:
26207848
DOI:
10.1111/bpa.12292
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center